Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis.


Journal

Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 23 12 2017
medline: 10 5 2020
entrez: 23 12 2017
Statut: ppublish

Résumé

Hematoxylin and eosin (H&E) staining is a well-established technique in histopathology. However, immunohistochemistry (IHC) interpretation is done exclusively with hematoxylin counterstaining. Our goal was to investigate the potential of H&E as counterstaining (H&E-IHC) to allow for visualization of a marker while confirming the diagnosis on the same slide. The quality of immunostaining and the fast-technical performance were the main criteria to select the final protocol. We stained multiple diagnostic tissues with class I IHC tests with different subcellular localization markers (anti-CK7, CK20, synaptophysin, CD20, HMB45, and Ki-67) and with double-staining on prostate tissues with anti-high molecular weight keratins/p63 (DAB detection) and p504s (alkaline phosphatase detection). To validate the efficacy of the counterstaining, we stained tissue microarrays from the Canadian Immunohistochemistry Quality Control (cIQc) with class II IHC tests (ER, PR, HER2, and p53 markers). Interobserver and intraobserver concordance was assessed by κ statistics. Excellent agreement of H&E-IHC interpretation was observed in comparison with standard IHC from our laboratory (κ, 0.87 to 1.00), and with the cIQc reference values (κ, 0.81 to 1.00). Interobserver and intraobserver agreement was excellent (κ, 0.89 to 1.00 and 0.87 to 1.00, respectively). We therefore show for the first time the potential of using H&E counterstaining for IHC interpretation. We recommend the H&E-IHC protocol to enhance diagnostic precision for the clinical workflow and research studies.

Identifiants

pubmed: 29271792
doi: 10.1097/PAI.0000000000000626
doi:

Substances chimiques

Biomarkers, Tumor 0
Neoplasm Proteins 0
Eosine Yellowish-(YS) TDQ283MPCW
Hematoxylin YKM8PY2Z55

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

558-563

Auteurs

Andrée-Anne Grosset (AA)

Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM).
Institut du cancer de Montréal.
Department of Pathology and Cellular Biology, Faculty of Medicine, Université de Montréal.

Kevin Loayza-Vega (K)

Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM).
Institut du cancer de Montréal.

Éloïse Adam-Granger (É)

Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM).
Institut du cancer de Montréal.

Mirela Birlea (M)

Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM).
Institut du cancer de Montréal.

Blake Gilks (B)

Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada.

Bich Nguyen (B)

Department of Pathology and Cellular Biology, Faculty of Medicine, Université de Montréal.
Department of Pathology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC.

Geneviève Soucy (G)

Department of Pathology and Cellular Biology, Faculty of Medicine, Université de Montréal.
Department of Pathology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC.

Danh Tran-Thanh (D)

Department of Pathology and Cellular Biology, Faculty of Medicine, Université de Montréal.
Department of Pathology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC.

Roula Albadine (R)

Department of Pathology and Cellular Biology, Faculty of Medicine, Université de Montréal.
Department of Pathology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC.

Dominique Trudel (D)

Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM).
Institut du cancer de Montréal.
Department of Pathology and Cellular Biology, Faculty of Medicine, Université de Montréal.
Department of Pathology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH